Egalet Corp. (NASDAQ:EGLT) shares fell 1% during trading on Thursday . The stock traded as low as $7.95 and last traded at $8.02, with a volume of 150,969 shares. The stock had previously closed at $8.10.

EGLT has been the subject of several recent research reports. Cantor Fitzgerald set a $21.00 price target on Egalet Corp. and gave the company a “buy” rating in a research note on Saturday, August 6th. Zacks Investment Research downgraded Egalet Corp. from a “hold” rating to a “sell” rating in a research note on Thursday, May 12th.

The company’s market capitalization is $196.83 million. The firm’s 50-day moving average is $6.84 and its 200 day moving average is $6.58.

Egalet Corp. (NASDAQ:EGLT) last issued its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.15. The firm earned $3.45 million during the quarter, compared to analysts’ expectations of $3.83 million. The firm’s revenue was up 259.4% on a year-over-year basis. During the same period in the previous year, the business posted ($1.03) earnings per share. Equities analysts anticipate that Egalet Corp. will post ($3.47) earnings per share for the current fiscal year.

In other news, CEO Robert S. Radie sold 5,000 shares of the stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $5.07, for a total value of $25,350.00. Following the completion of the sale, the chief executive officer now directly owns 259,900 shares of the company’s stock, valued at $1,317,693. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Robert S. Radie sold 15,000 shares of the stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $5.01, for a total value of $75,150.00. Following the completion of the sale, the chief executive officer now directly owns 259,900 shares of the company’s stock, valued at $1,302,099. The disclosure for this sale can be found here.

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.